Purple Biotech Ltd (PPBT)
NASDAQ: PPBT · Real-Time Price · USD
0.7851
-0.1548 (-16.47%)
At close: Oct 31, 2025, 4:00 PM EDT
0.7655
-0.0196 (-2.50%)
After-hours: Oct 31, 2025, 7:59 PM EDT
Purple Biotech Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
9
Market Cap
8.33M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| Eli Lilly and Company | 59.42B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
PPBT News
- 2 days ago - Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform - GlobeNewsWire
- 11 days ago - Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification - GlobeNewsWire
- 2 months ago - Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants - GlobeNewsWire
- 2 months ago - Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 3 months ago - Purple Biotech Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025 - GlobeNewsWire
- 4 months ago - Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress - GlobeNewsWire
- 5 months ago - Purple Biotech Reports First Quarter 2025 Financial Results - GlobeNewsWire